Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
Ronald D'AmicoSantiago Cenoz GomisRiya MoodleyRodica Van Solingen-RisteaBryan BaughErika Van LanduytVeerle Van EygenSherene MinAmy CutrellCaroline FosterDaniella ChiltonSabine D AllardAnnemiek RuiterPublished in: HIV medicine (2022)
Most people living with HIV-1 had advanced disease and achieved (16/28) or maintained (6/7) virological suppression with LA therapy. Cabotegravir LA + rilpivirine LA as compassionate use provided a valuable treatment option for individuals with adherence issues with oral therapy and advanced disease.